// STATE LEGISLATION TRACKER

Kentucky HB 750: AN ACT relating to cychlorphine.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Kentucky
Bill: HB 750
Session: 2026RS
Filed: 2026-02-25
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Kentucky HB750 is a criminal-law bill focused on cychlorphine, a synthetic opioid, not peptides. Based on the title, subjects, and available summary, it does not appear to change access to compounded peptides, off-label peptide prescribing, telehealth care, naturopathic or NP scope, or FDA 503A/503B compounding rules.

Key Points

No direct peptide access change is indicated
No telehealth prescribing change is indicated
No NP or naturopathic scope change is indicated
No 503A or 503B compounding change is indicated
Bill targets cychlorphine importing, trafficking, and related deaths

What to Watch For

Note Watch whether later amendments broaden the bill beyond cychlorphine or controlled-substance crimes.

Note Clinics using peptides should still avoid vendors with mislabeled or illicit drug products.

Note The bill sits in the opioid enforcement lane, not the peptide or compounding lane.

Where the Bill Stands

The listed latest action is referral to the House Judiciary Committee on March 4, 2026, with no passage shown.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws